Canine Arrhythmias: Diagnostic Workup and Antiarrhythmic Selection

By Dr. Zubair Khalid, DVM, MS, PhD · 2026-08-11

Key Takeaways

• A 5-minute in-hospital ECG is a useful initial screening tool but has limited sensitivity for detecting intermittent arrhythmias, with Holter monitoring (24-hour ambulatory ECG) serving as the gold standard for comprehensive arrhythmia burden assessment.
• Antiarrhythmic drug selection is dictated by the arrhythmia mechanism (abnormal automaticity, triggered activity, reentry), underlying structural heart disease, and the presence of clinical signs, with sodium channel blockers for reentry/automaticity, calcium channel blockers for triggered activity, and beta-blockers for sympathetic drive.
• Hemodynamic significance and risk of degeneration to life-threatening rhythms are critical factors in determining the need for antiarrhythmic therapy; asymptomatic, low-frequency ventricular premature complexes in structurally normal dogs often do not require treatment.
• Monitoring for therapeutic efficacy and proarrhythmia is essential, typically involving repeat ECG or Holter monitoring, with acceptable endpoints focusing on suppression of clinically significant arrhythmias rather than complete ectopy elimination.
• Referral to a veterinary cardiologist is indicated for persistent complex ventricular arrhythmias, syncope unresponsive to initial therapy, suspected cardiomyopathy, or when pacemaker implantation is being considered.
• Computerized ECG algorithms offer high sensitivity for arrhythmia detection but require manual review due to lower specificity for other ECG anomalies, emphasizing the practitioner's role in integrating ECG findings with the overall clinical picture.

This article provides a systematic framework for the diagnosis and management of arrhythmias in dogs, written for the practicing veterinarian who encounters cardiac rhythm disturbances in general practice. It addresses the diagnostic reasoning pathway from initial suspicion through electrocardiographic confirmation, risk stratification, and drug selection based on arrhythmia type and mechanism. The content assumes familiarity with clinical terminology and basic electrocardiography, and it focuses on acquired arrhythmias in dogs without congenital heart disease.

The approach presented here integrates the physiologic basis of cardiac electrical activity with practical diagnostic tools and therapeutic decision-making. Arrhythmia management in dogs is complicated by the intermittent nature of many rhythm disturbances, the limitations of short electrocardiogram (ECG) recordings, and the variable prognostic significance of identical arrhythmias in different clinical contexts. A structured diagnostic workup that matches the diagnostic tool to the clinical question reduces both underdiagnosis and unnecessary treatment.

At a Glance

Physiologic Basis of Arrhythmogenesis

Cardiac action potentials arise from coordinated ion channel activity across the myocardial cell membrane. The phases of the action potential reflect sequential activation and inactivation of sodium, calcium, and potassium currents, and the ECG records the summated electrical activity of the myocardium as these currents propagate. Understanding the ion channel basis of normal automaticity and conduction is prerequisite to interpreting arrhythmia mechanisms and predicting drug responses, as antiarrhythmic agents act by modifying specific ion currents. Comparative reviews of cardiac ion channels and action potentials across species provide the translational framework for this understanding, although species differences in channel expression and ECG morphology limit direct extrapolation from rodent models to canine clinical practice A comparative review on heart ion channels, action potentials and electrocardiogram in rodents and human.

Three fundamental mechanisms generate arrhythmias: abnormal automaticity, triggered activity, and reentry. Abnormal automaticity arises from enhanced phase 4 depolarization in pacemaker tissue or from depolarized myocytes that acquire pacemaker activity. Triggered activity results from afterdepolarizations, either early or delayed, that reach threshold and generate an extrasystole. Reentry requires a circuit of conduction block and slow conduction that allows a wavefront to re-excite tissue that has recovered excitability. The mechanism matters clinically because drug selection differs: sodium channel blockade suppresses reentry and abnormal automaticity, calcium channel blockade targets triggered activity and slow conduction, and beta blockade reduces sympathetic drive to automatic foci.

Electrocardiographic Diagnosis

Recording and Interpretation

The standard 6-lead ECG remains the first-line diagnostic tool for suspected arrhythmia. A 5-minute recording is the minimum practical duration for in-hospital assessment, but its diagnostic yield is limited by the intermittent nature of many arrhythmias. In Doberman Pinschers with occult cardiomyopathy, a 5-minute ECG containing at least one ventricular premature contraction had a sensitivity of only 64.2% for detecting more than 100 ventricular premature contractions per 24 hours on Holter monitoring, despite a specificity of 96.7% Ability of a 5-minute electrocardiography (ECG) for predicting arrhythmias in Doberman Pinschers with cardiomyopathy. A negative 5-minute ECG therefore does not exclude significant arrhythmia burden, and a positive finding is highly specific.

Computerized ECG algorithms can assist interpretation, but their limitations must be recognized. One evaluation of a commercial algorithm against a panel of board-certified cardiologists found high sensitivity for arrhythmia detection at 99.7%, yet sensitivity for any ECG anomaly including abnormal measurements was only 71.3% with a specificity of 35.1% Diagnostic accuracy of computer aided electrocardiogram analysis in dogs. The algorithm reliably flagged the presence of arrhythmia but frequently misclassified other abnormalities. Practitioners should use automated interpretations as a screening filter and personally review every tracing.

Ambulatory Monitoring

Holter monitoring provides the reference standard for quantifying arrhythmia burden over 24 hours. Indications include syncope or collapse with a normal in-hospital ECG, evaluation of suspected cardiomyopathy in predisposed breeds, assessment of antiarrhythmic drug efficacy, and characterization of arrhythmia frequency and complexity. The Holter report should include total ventricular premature contraction count, presence of couplets or runs of ventricular tachycardia, and the relationship of arrhythmia to heart rate and activity.

The choice between 5-minute ECG and Holter depends on the clinical question. For a dog with an irregular rhythm detected on physical examination, a 5-minute ECG may confirm the diagnosis. For a dog with unexplained syncope, Holter monitoring is the appropriate test because a short recording is unlikely to capture an intermittent event. Breed-specific screening protocols, such as those used in Doberman Pinschers and Boxers, rely on Holter-derived arrhythmia counts to identify affected dogs before the onset of clinical signs.

Clinical Context and Risk Stratification

Arrhythmia significance depends on the clinical context in which it occurs. A ventricular premature contraction in a young dog with no structural heart disease carries different prognostic weight than the same arrhythmia in a Doberman Pinscher with echocardiographic evidence of cardiomyopathy. The diagnostic workup must therefore include assessment for underlying structural heart disease, electrolyte abnormalities, systemic illness, and drug exposure.

Breed predisposition influences both the pretest probability of arrhythmia and the interpretation of findings. Borzoi dogs evaluated by veterinary cardiologists most commonly presented for pre-breed screening, and ventricular arrhythmias were identified in 19% of dogs with an available echocardiographic diagnosis, often in structurally normal hearts A multicenter, retrospective study of cardiac disease in Borzoi dogs. This finding illustrates that ventricular arrhythmias in sighthounds may occur without identifiable structural disease, and it underscores the need for breed-specific reference data when interpreting Holter results.

Survey data from veterinary practitioners reveal that insufficient confidence in ECG interpretation is a major barrier to arrhythmia diagnosis and treatment. In one cross-sectional survey of Flemish veterinarians, an ECG device was available to only 54% of respondents, and 43% used it when arrhythmia was suspected. Insufficient knowledge about ECG interpretation and immediate referral upon detection of an abnormal rhythm were the most commonly cited reasons for not using an ECG, and 56% of respondents had never used antiarrhythmic drugs Diagnosis and management of arrhythmias in dogs: A cross-sectional online survey among Flemish veterinary practitioners. These findings highlight the need for a structured diagnostic approach that builds confidence through systematic interpretation instead of pattern recognition alone.

Diagnostic Decision Framework

The diagnostic workup proceeds through defined steps. First, confirm the arrhythmia with an appropriate recording modality. Second, characterize the arrhythmia by mechanism, site of origin, frequency, and complexity. Third, identify any underlying structural or systemic disease. Fourth, determine whether the arrhythmia requires treatment based on hemodynamic impact and risk of degeneration to a life-threatening rhythm.

The decision to treat rests on the presence of clinical signs attributable to the arrhythmia, the arrhythmia burden, and the underlying cardiac disease. Asymptomatic dogs with low-frequency ventricular premature contractions and no structural heart disease may not require antiarrhythmic therapy. Conversely, dogs with syncope, congestive heart failure, or high-grade ventricular arrhythmias warrant treatment regardless of the absence of clinical signs between episodes.

Indications for Antiarrhythmic Therapy

Not every arrhythmia requires treatment. The decision to intervene rests on hemodynamic compromise, risk of degeneration into a life-threatening rhythm, or the presence of clinical signs directly attributable to the arrhythmia. Syncope, episodic weakness, congestive heart failure, or collapse in association with a documented tachyarrhythmia are clear indications. Asymptomatic dogs with occasional ventricular premature complexes (VPCs) and no structural heart disease often require no therapy beyond monitoring.

The most difficult decisions arise in breeds with heritable cardiomyopathy. In Doberman Pinschers, a 5-minute ECG detects only 64.2% of dogs with more than 100 VPCs per 24 hours, so a normal short recording does not exclude clinically important arrhythmia burden Wess G, et al. Ability of a 5-minute electrocardiography (ECG) for predicting arrhythmias in Doberman Pinschers with cardiomyopathy in comparison with a 24-hour ambulatory ECG. Conversely, a single VPC on a 5-minute trace carries a positive predictive value of 85.6% for significant 24-hour burden in this breed, making Holter confirmation appropriate before committing to long-term therapy.

The presence of structural heart disease changes the risk calculus. Ventricular arrhythmias in a dog with dilated cardiomyopathy, myocarditis, or severe valvular disease warrant more aggressive management than the same rhythm in a structurally normal heart. Similarly, arrhythmias that occur during anesthesia, after trauma, or in the setting of electrolyte disturbance require treatment of the inciting cause first. Antiarrhythmic drugs are supportive, not curative, and therapy directed at the arrhythmia alone will fail if the underlying trigger persists.

Drug Selection by Arrhythmia Type

Ventricular Arrhythmias

Class I agents, particularly lidocaine and mexiletine, block sodium channels and are most effective in suppressing VPCs and ventricular tachycardia. Lidocaine is administered intravenously for acute management of hemodynamically significant ventricular tachycardia. Mexiletine is the oral congener and is often combined with a Class II beta-blocker such as sotalol or atenolol to achieve additive suppression while limiting adverse effects.

Sotalol, a Class III agent with beta-blocking properties, is a first-line oral option for chronic suppression of ventricular arrhythmias in many dogs. Amiodarone is reserved for refractory or life-threatening cases because of its long half-life, tissue accumulation, and potential for hepatotoxicity, pulmonary fibrosis, and thyroid dysfunction. The choice between sotalol and mexiletine plus a beta-blocker is often empirical, guided by the underlying disease, concurrent medications, and the dog's systemic blood pressure.

Supraventricular Arrhythmias

Atrial fibrillation is the most common supraventricular tachyarrhythmia in dogs. The therapeutic goals are rate control and, in selected cases, conversion to sinus rhythm. Diltiazem, a calcium channel blocker, is the most frequently used agent for rate control. Beta-blockers such as atenolol are alternatives, particularly when concurrent sympathetic tone is high. Digoxin provides additional rate control but has a narrow therapeutic index and is rarely sufficient as monotherapy.

Atrial premature complexes that are infrequent and asymptomatic do not require treatment. When they are frequent, provoke atrial fibrillation, or occur in a dog with underlying atrial disease, diltiazem or a beta-blocker may be considered. Supraventricular tachycardia in young dogs without structural heart disease may respond to vagal maneuvers acutely, but chronic management typically requires a calcium channel blocker or beta-blocker.

Bradyarrhythmias

Sinus bradycardia, atrial standstill, and high-grade atrioventricular block are generally not responsive to oral antiarrhythmic drugs. Atropine is used diagnostically and for acute management of vagally mediated bradycardia. When bradyarrhythmia is symptomatic or associated with syncope, permanent pacemaker implantation is the definitive therapy. Medical management with positive chronotropes such as terbutaline or theophylline is inconsistently effective and is reserved for dogs that are not pacemaker candidates.

Monitoring and Therapeutic Endpoints

The goal of antiarrhythmic therapy is not the complete elimination of all ectopy. Suppression of clinically significant arrhythmia, defined as resolution of syncope or weakness, reduction in ventricular tachycardia episodes, and improvement in hemodynamic stability, is an acceptable endpoint. Attempting to abolish every VPC often requires drug doses that produce intolerable adverse effects.

Repeat Holter monitoring is the standard method for assessing therapeutic response. The timing of re-evaluation depends on the drug, the arrhythmia, and the clinical context. A dog started on sotalol for ventricular tachycardia should have a repeat Holter within one to two weeks to confirm suppression and to assess for proarrhythmia. Serum drug concentrations are available for some agents, including digoxin and mexiletine, and are useful when efficacy is inadequate or toxicity is suspected.

Adverse Effects and Proarrhythmia

All antiarrhythmic drugs have the capacity to worsen the very arrhythmia they are meant to suppress. Proarrhythmia is most concerning with Class I and Class III agents. Mexiletine can cause gastrointestinal signs, tremors, and ataxia at higher doses. Sotalol may provoke torsades de pointes, particularly in dogs with hypokalemia or prolonged QT interval. Amiodarone carries the highest burden of extracardiac toxicity and should be reserved for arrhythmias refractory to safer agents.

Drug interactions are clinically relevant. Combining mexiletine with a beta-blocker is common and generally well tolerated, but adding a calcium channel blocker to a beta-blocker can produce profound bradycardia and hypotension. Digoxin toxicity is potentiated by hypokalemia, azotemia, and concurrent administration of amiodarone or verapamil. Serum chemistry and electrolyte monitoring should accompany any antiarrhythmic drug adjustment.

Documentation and Referral

Every arrhythmia evaluation should produce a written record that includes the presenting complaint, the ECG tracing or a representative strip, the arrhythmia diagnosis with a description of morphology and rate, the Holter summary if performed, the echocardiographic findings, and the rationale for the chosen therapy. This documentation supports serial comparison and facilitates communication with a cardiologist if referral becomes necessary.

Referral to a veterinary cardiologist is appropriate when the arrhythmia is refractory to first-line therapy, when syncope persists despite treatment, when the dog has structural heart disease and complex ventricular arrhythmias, or when pacemaker implantation is being considered. Many practitioners lack confidence in ECG interpretation and antiarrhythmic drug use, as identified in a survey of Flemish veterinarians where insufficient knowledge was the most common reason for not using an ECG or antiarrhythmic drugs Hellemans A, et al. Diagnosis and management of arrhythmias in dogs: A cross-sectional online survey among Flemish veterinary practitioners. Computerized ECG algorithms can detect arrhythmias with high sensitivity, but they do not replace a systematic clinical interpretation, particularly for subtle measurement abnormalities Estrada AH, et al. Diagnostic accuracy of computer aided electrocardiogram analysis in dogs. The practitioner's role is to integrate the ECG with the full clinical picture, select therapy based on arrhythmia mechanism and underlying disease, and monitor for both efficacy and toxicity.

Recognized Complications and Early Detection

Antiarrhythmic therapy carries inherent risk, and the most serious failure mode is proarrhythmia. Drug-induced worsening of the existing arrhythmia, or emergence of a new arrhythmia, can occur with any agent but is most concerning with class III drugs and with sodium channel blockers in patients with structural heart disease. Early detection requires a systematic approach: repeat ECG at the time of expected peak drug effect, re-evaluation after any dose adjustment, and ambulatory monitoring when the presenting arrhythmia was intermittent. Owners should be instructed to report syncope, collapse, or apparent weakness, as these signs may indicate hemodynamically significant proarrhythmia instead of therapeutic failure.

Hypotension and negative inotropy are predictable complications of many antiarrhythmics, particularly beta blockers and calcium channel blockers. Patients with pre-existing myocardial dysfunction are at greatest risk. Baseline echocardiographic assessment of systolic function before initiating these agents is therefore prudent. Serial blood pressure measurement and assessment of mucous membrane color, pulse quality, and mentation at each recheck provide practical surveillance.

Bradyarrhythmia may emerge during therapy for tachyarrhythmias, especially when combination therapy is used. Sinus bradycardia, atrioventricular block, or sinus arrest should prompt dose reduction or discontinuation. Conversely, acceleration of ventricular response during atrial fibrillation can occur with class IC agents, which slow atrial rate without prolonging atrioventricular nodal refractoriness. This failure mode is detected by comparing ventricular rate before and after drug initiation.

Common Errors and Corrective Actions

Insufficient ECG interpretation skill is the most frequently cited barrier to arrhythmia diagnosis among practitioners, and this limitation drives both underuse of ECG and premature referral. Computerised ECG algorithms demonstrate high sensitivity for arrhythmia detection but substantially lower specificity for other ECG anomalies, so automated interpretations should be verified against the raw trace instead of accepted verbatim. A 5-minute ECG is insensitive for detecting paroxysmal ventricular arrhythmias, missing roughly one-third of Doberman Pinschers with more than 100 VPCs per 24 hours. Reliance on a single short recording to exclude clinically important arrhythmia is therefore a common and consequential error.

Treating the ECG tracing instead of the patient is another frequent mistake. Isolated VPCs in a structurally normal dog with no clinical signs may not require therapy, whereas the same arrhythmia in a Doberman Pinscher with echocardiographic cardiomyopathy carries different prognostic weight. The decision to treat should integrate signalment, breed predisposition, structural findings, and clinical signs, not the mere presence of ectopy.

A third error is failure to characterize the arrhythmia before selecting a drug. Supraventricular and ventricular arrhythmias require different agents, and some drugs are contraindicated in specific arrhythmia types. A structured diagnostic framework that includes a minimum of 5 minutes of continuous ECG, echocardiography, and ambulatory monitoring when clinically indicated reduces this risk.

Limitations of Current Evidence

The evidence base for canine antiarrhythmic therapy is constrained by a scarcity of prospective randomised trials. Most recommendations derive from retrospective studies, expert consensus, and extrapolation from human medicine. Breed-specific data exist for some populations, such as Doberman Pinschers and Borzoi, but these findings may not transfer to other breeds. The ACVIM consensus statements synthesise available evidence and expert opinion, and they remain the most useful single reference for clinical decision-making, but they also acknowledge areas where evidence is insufficient to support firm recommendations.

Expert opinion diverges on several practical points. The threshold for initiating antiarrhythmic therapy in asymptomatic dogs with ventricular arrhythmias is not uniformly agreed. Some cardiologists treat based on VPC frequency or complexity, while others defer therapy until syncope or hemodynamic compromise occurs. Similarly, the role of routine antiarrhythmic therapy in dogs with dilated cardiomyopathy but no documented arrhythmia remains contested. These disagreements reflect the absence of outcome data linking treatment to survival benefit.

Referral, Consultation, and Reporting

Referral to a veterinary cardiologist is warranted when arrhythmias are refractory to initial therapy, when syncope recurs despite treatment, when the arrhythmia is associated with structural heart disease of uncertain severity, or when Holter monitoring and interpretation are not available locally. Cardiologists can provide advanced diagnostics including intracardiac electrophysiologic studies and interventional therapies such as pacemaker implantation or catheter ablation.

Laboratory involvement is indicated when electrolyte disturbances, particularly potassium or magnesium abnormalities, are suspected as precipitating factors. Serial measurement of serum drug concentrations is not routinely performed for most veterinary antiarrhythmic agents, but it may be available for some drugs through commercial laboratories and can guide dosing when therapeutic failure or toxicity is suspected.

Regulatory reporting obligations vary by jurisdiction. Adverse drug events, including suspected proarrhythmia or death attributable to an antiarrhythmic agent, should be reported to the relevant national pharmacovigilance program. Practitioners should consult their national veterinary authority or professional body for current reporting requirements. The AVMA provides practice resources that include guidance on adverse event reporting and professional obligations.

Frequently Asked Questions

How should I proceed when a Holter monitor is unavailable or cost-prohibitive?

A 5-minute in-clinic ECG can serve as a screening test, but its limitations must be acknowledged. In Doberman Pinschers, a 5-minute ECG containing at least one ventricular premature complex had a sensitivity of only 64.2% for detecting more than 100 VPCs per 24 hours, meaning over one third of affected dogs were missed. When Holter monitoring is not feasible, consider serial short ECGs, event-triggered recording if the device supports it, or referral to a cardiology service that can provide ambulatory monitoring. Document the screening method used and its known sensitivity constraints in the medical record so that subsequent clinicians interpret negative results appropriately.

What should I do if my ECG machine's automated interpretation conflicts with my manual reading?

Automated algorithms perform well for arrhythmia detection but less reliably for other ECG anomalies. One evaluation of a commercial algorithm reported 99.7% sensitivity for arrhythmia detection yet only 71.3% sensitivity for any ECG anomaly, with specificity falling to 35.1%. You should therefore treat the automated report as a screening tool, not a final diagnosis. Manually verify intervals, morphology, and rhythm interpretation before initiating therapy. If the discrepancy involves a finding that would change drug selection, obtain a second opinion or consult a cardiologist. Record both the automated and manual interpretations in the patient record.

How do I explain the need for antiarrhythmic therapy to a client who is reluctant about cost or medication?

Frame the discussion around risk instead of diagnosis alone. Explain that the ECG identifies an electrical disturbance that may predispose the dog to collapse or sudden death, and that the medication reduces that risk. Provide a concrete monitoring plan, including follow-up ECG or Holter dates, so the client understands the treatment is time-limited or adjustable. If cost is the barrier, discuss whether a shorter monitoring interval or a less expensive drug class is appropriate for the specific arrhythmia. Referral to a cardiologist may be reasonable when the client needs additional reassurance or when the arrhythmia is complex.

When should I refer a case to a cardiologist instead of manage it in general practice?

Refer when the arrhythmia is refractory to initial therapy, when syncope or collapse occurs despite treatment, when the arrhythmia is associated with structural heart disease of uncertain severity, or when you are considering a drug with a narrow therapeutic index. Referral is also appropriate when Holter monitoring is indicated but unavailable, or when the ECG shows complex ventricular ectopy, sustained tachyarrhythmias, or high-grade atrioventricular block. Practitioners who report limited confidence in ECG interpretation are more likely to refer, and this is a reasonable threshold for seeking specialist input. Early referral is preferable to delayed referral after a failed treatment trial.

How should I document arrhythmia management in the medical record for medicolegal protection?

Record the indication for the ECG, the rhythm diagnosis, the drug selected with the rationale, and the specific monitoring endpoints you intend to use. Note the client discussion, including risks of the arrhythmia and the adverse effects of the proposed medication. When a drug is prescribed, document the dose, the planned recheck interval, and the parameters that would prompt dose adjustment or discontinuation. If you deviate from published guidelines or formulary recommendations, state the clinical justification. This documentation supports continuity of care and provides a defensible record if the outcome is poor.

Does the diagnostic approach differ for sighthounds or other breeds with physiologic arrhythmias?

Yes. Breed-specific considerations can alter the pretest probability of clinically significant arrhythmias. In Borzoi, ventricular arrhythmias were identified in 19% of dogs undergoing cardiac evaluation, yet many of these dogs were structurally normal, suggesting that some rhythm disturbances in sighthounds may be breed-related instead of pathologic. The same ECG finding in a Doberman Pinscher carries different prognostic weight because of the strong association with cardiomyopathy. Interpret arrhythmias in the context of breed, age, and echocardiographic findings, and consult breed-specific literature when available. When uncertainty remains, Holter monitoring and cardiology referral are appropriate.

Related Clinical & Scientific Guides

• Feline Hepatic Lipidosis: Nutritional and Medical Management
• Canine Respiratory Infection: Diagnostic Approach and Treatment
• Canine Respiratory Virus: Diagnostic and Management Considerations

References and Further Reading

• A comparative review on heart ion channels, action potentials and electrocardiogram in rodents and human: extrapolation of experimental insights to clinic.. 2021.
• Diagnosis and management of arrhythmias in dogs: A cross-sectional online survey among Flemish veterinary practitioners.. 2022.
• Diagnostic accuracy of computer aided electrocardiogram analysis in dogs.. 2021.
• Use of Artificial Intelligence to Detect Cardiac Rhythm Disturbances in Athletes: A Scoping Review.. 2025.
• A multicenter, retrospective study of cardiac disease in Borzoi dogs.. 2023.
• Ability of a 5-minute electrocardiography (ECG) for predicting arrhythmias in Doberman Pinschers with cardiomyopathy in comparison with a 24-hour ambulatory ECG.. 2010.
• ACVIM Consensus Statements. Journal of Veterinary Internal Medicine.
• MSD Veterinary Manual, Professional Edition. MSD Veterinary Manual.
• American Veterinary Medical Association Practice Resources. American Veterinary Medical Association.

Related Articles

• Canine Hypoadrenocorticism: Diagnostic and Therapeutic Monitoring
• Canine Proteinuria: Diagnostic Approach and Management
• Canine Endocrine Testing: Interpretation and Diagnostic Strategy
• Canine Epilepsy: Antiepileptic Drug Selection and Monitoring
• Canine Vomiting: Diagnostic Approach for Pancreatitis

This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.